Purpose
To provide timely information about shortages related to STI testing and treatment products.
NOTICE
- Visit the FDA's Drug Shortages page for information on all current and resolved drug shortages and discontinuations reported to the U.S. Food & Drug Administration (FDA).
- Notify DSTDP (stdshortages@cdc.gov) of any shortage or low inventories of STI treatments in your jurisdiction so CDC can continue monitoring treatment availability.
Bicillin L-A®
On July 10, 2025, King Pharmaceuticals, a subsidiary of Pfizer, issued a voluntary recall of specific referenced lots of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension). Further details and priority actions for health departments and healthcare providers are available from the Dear Colleague Letter.
On 1/16/2024, the FDA announced that they have exercised enforcement discretion for a temporary importation and use of Extencillin (benzathine benzylpenicillin injection, powder, for suspension). See more in this CDC letter. See more in this CDC letter. Temporary Importation of Lentocilin, (Benzathine Benzylpenicillin Tetrahydrate) Powder and diluent for suspension for injection, has also been allowed since July of 2024.
Bicillin L-A® is the first-line recommended treatment for syphilis and the only recommended treatment option for some patients.
CDC continues to monitor the situation and will post updates as needed.